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Quantitative genetics of renal 
function: tackling complexities 
of the eGFR phenotype in gene 
mapping studies
Krzysztof Kiryluk1
The linkage approach to quantitative traits, such as estimated 
glomerular filtration rate (eGFR), has been utilized in several recent 
studies aimed at identification of susceptibility loci. However, the 
heterogeneity and complex architecture of the eGFR phenotype make 
the gene mapping efforts inherently difficult. Mottl and colleagues 
attempt to tackle this problem in their analysis of a unique family-
based cohort of American Indians.
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Chronic kidney disease (CKD), defined by 
proteinuria and reduced estimated glomer-
ular filtration rate (eGFR), affects over 
10% of the adult population of the United 
States.1 An abundance of data supports the 
importance of genetic factors in the patho-
genesis of CKD. These data include signifi-
cant differences in the prevalence of CKD 
among specific ethnic/ancestral groups2–5 
and familial aggregation of the disease.6–8 
Although tremendous progress has been 
made in the identification of genes respon-
sible for mendelian forms of renal disease, 
elucidation of genetic factors that predis-
pose to CKD has not been very successful. 
The most likely obstacle is the complexity 
of the CKD phenotype. As CKD is an end 
point of many pathologic processes, it is 
probably a heterogeneous disease deter-
mined by many genes and gene–gene 
and gene–environment interactions. The 
effect of individual genes may be too small 
to permit their detection by the traditional 
genetic methods based on linkage analy-
sis. Thus, as with other common complex 
diseases, the CKD genes are substantially 
harder to identify than rare genes with 
large effect sizes that are involved in men-
delian disorders.
The past 10 years have been marked by 
considerable progress in the field of com-
plex-disease genetics. Both the quantitative 
linkage and the genetic association meth-
ods have been developed and successfully 
applied to detect genes underlying com-
plex phenotypes. In quantitative linkage 
analysis, the chromosomal susceptibility 
regions (quantitative trait loci) are iden-
tified by modeling of the observed cor-
relations between the phenotypic traits of 
relatives as a function of the alleles shared 
by descent. This type of analysis is cur-
rently dominated by methods based on 
the variance component approach, devel-
oped in the mid-1990s.9,10 The variance 
component method has been successfully 
used to map many human quantitative 
trait loci and has facilitated the identi-
fication of several human disease genes 
by positional cloning.11 In comparison 
with traditional linkage approaches, this 
method is less sensitive to genetic hetero-
geneity, but its power remains limited to 
genes that have relatively large independ-
ent effects. In contrast, genetic association 
studies do not depend on observation of 
correlations among relatives and can be 
performed on samples of unrelated indi-
viduals. This approach offers considerably 
more power to detect common genetic 
variants with moderate to relatively small 
effects.12 In addition, the introduction of 
high-density single-nucleotide polymor-
phism genotyping platforms has enabled 
association studies at a genome-wide level. 
Since the landmark study of age-related 
macular degeneration in 2005,13 genome-
wide association studies have identified 
more than 100 chromosomal regions that 
influence the risk of common diseases 
in humans.14
Although genome-wide association stud-
ies for CKD are under way, the majority of 
published studies have used the quantita-
tive linkage approach. In these studies, 
eGFR has been adopted as a quantitative 
correlate of kidney function. Because eGFR 
exhibits a continuous phenotypic spectrum, 
its use as an endo-phenotype in genetic 
studies offers more precision and more 
information about CKD severity than the 
threshold-defined CKD stages. Heritability 
of eGFR, which is a measure of how much 
of the trait’s variability can be attributed to 
genetic causes and is calculated by obser-
vation of phenotypic correlations between 
relatives in families, is estimated to range 
from 0.25 to 0.75 depending on a study 
population and included covariates.15–20 
Despite high heritability estimates, the 
identification of specific genes contribut-
ing to eGFR variation remains extremely 
challenging. Genetic heterogeneity contin-
ues to be a major problem, as many factors 
that may have different genetic regulation 
influence eGFR variability. The complex 
genetic architecture of eGFR requires stud-
ies of large sample size to achieve adequate 
power for dissection of interacting genetic 
and environmental factors. Although there 
is a possibility that a biologic predisposi-
tion to GFR loss exists independently of any 
specific etiologic insult, a variety of normal 
physiologic states also affect eGFR, and, 
even within a single disease process, eGFR 
determination may be quite complex. For 
example, in early stages of diabetic neph-
ropathy, eGFR is frequently increased, and 
this phenomenon may be misleading in a 
quantitative genetic model that assumes 
a linear relationship between the trait 
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(eGFR) and a disease risk allele. Further-
more, the Modification of Diet in Renal 
Disease (MDRD) estimation is inaccurate 
in healthy individuals with GFR in a high-
normal range. The estimation of GFR is also 
confounded by the common use of medi-
cations blocking the renin–angiotensin 
system. Multiple other environmental fac-
tors, including the ones known from CKD 
epidemiology as well as many yet unrecog-
nized, cloud the picture.
Although the quantitative genetic 
approach offers methodology to dissect 
such random effects, some of the envi-
ronmental variables associated with eGFR 
may have a strong genetic determination 
themselves (Figure 1). In these situations, 
the results of linkage analyses that do not 
account for such variables may be difficult 
to interpret, as the genes underlying linkage 
peaks may, for example, be involved in the 
susceptibility to diabetes, hypertension, or 
obesity, rather than being directly involved 
in eGFR determination. Therefore, in order 
to increase the genetic signal-to-noise ratio, 
a careful multivariate analysis is typically 
necessary. Apart from being helpful in 
the interpretation of linkage peaks, multi-
variate analysis improves the robustness of 
findings that withstand refutation under a 
variety of models. Finally, using a genome-
wide search strategy further complicates 
interpretation of results, with a multiple-
testing problem inflating the likelihood 
of false-positive findings. Although this 
problem can be partially overcome by the 
selection of stringent significance criteria, 
permutation-based statistical procedures, 
and adequately powered sample sizes, rep-
lication of findings is usually required.
Despite the above challenges, Mottl and 
colleagues have undertaken a new search 
for loci predisposing to eGFR loss in a large 
family-based cohort from 13 American 
Indian tribes, and they report their findings 
in this issue of Kidney International.21 In 
their unique cohort, the authors estimate 
the heritability of eGFR at approximately 
30%. Detailed phenotypic characteriza-
tion reveals a high prevalence of diabetes, 
hypertension, hypercholesterolemia, and 
obesity, as well as CKD, in this popula-
tion. In the genome-wide microsatellite 
scan, the most significant linkage find-
ing is that of a lod score of 3.5 at a locus 
on chromosome 12p12.2. This signal is 
observed only in a subgroup from Ari-
zona, composed primarily of Pima Indi-
ans. The lod score increases to 4.6 after 
exclusion of individuals on antihyperten-
sive medications, presumably because of 
elimination of the confounding effects of 
renin−angiotensin antagonists, but it drops 
to 2.1 after correction for other important 
covariates and disappears when the entire 
cohort is analyzed jointly. Although a sug-
gestive linkage peak in the same region has 
been observed in one of the subgroups in a 
prior genome-wide scan for diabetic neph-
ropathy in African Americans,22 further 
efforts are clearly needed to validate this 
broad locus and narrow down the candi-
date interval to enable identification of the 
causative gene.
In order to put this study in perspective, 
previous attempts to identify major quan-
titative trait loci responsible for eGFR loss 
are summarized in Table 1. Most other 
groups concentrated on specific CKD risk 
populations, such as diabetics23 and hyper-
tensives,24,25 although community-based 
eGFR linkage studies have also been con-
ducted.16,17 As may be expected for a com-
plex trait, multiple linkage peaks have been 
observed. Disappointingly, there is very 
little overlap in the detected loci between 
different studies. This may be due to hetero-
geneous study populations, but differences 
in methods and statistical modeling strate-
gies may also contribute. In addition, most 
prior studies test several traits (for example, 
Cr, CrCl, eGFR) in multiple subgroups (for 
example, diabetics versus nondiabetics ver-
sus combined, and so on), using multiple 
statistical models at a genome-wide level. 
Not surprisingly, many false-positive peaks 
are being generated. Unfortunately, most 
study designs suffer from a lack of a ‘built-
in’ replication phase, and investigators 
rarely pursue fine-mapping of candidate 
regions with a denser map of markers—a 
procedure that may further strengthen the 
evidence for linkage or reject false peaks. 
Finally, power calculations for these stud-
ies are not straightforward, and they are 
not routinely performed, which means 
that many studies are covertly underpow-
ered. Notwithstanding these limitations, 
quantitative mapping studies continue to 
provide valuable insights into genetic het-
erogeneity of eGFR and outline the land-
scape of ‘high-priority’ candidate regions. 
Looking forward, whole-genome quantita-
tive genetic association studies may hold 
promise to provide independent support 
for the prospective candidate intervals 
and point to specific genes involved in the 
eGFR determination.
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Figure 1 | Simplified view of a complex relationship between genetic and environmental 
factors in eGFR determination. Red arrow illustrates independent effects of genes that remain to 
be identified; eGFR refers to GFR estimate based on serum creatinine, age, sex, and race.
Kidney International (2008) 74          1111
commentar y
ReFeRenceS
1. Coresh J, Astor BC, Greene T et al. Prevalence of 
chronic kidney disease and decreased kidney 
function in the adult US population: Third National 
Health and Nutrition Examination Survey. Am J 
Kidney Dis 2003; 41: 1–12.
2. Ferguson R, Grim CE, Opgenorth TJ. A familial risk of 
chronic renal failure among blacks on dialysis?  
J Clin Epidemiol 1988; 41: 1189–1196.
3. Freedman BI, Spray BJ, Tuttle AB, Buckalew VM Jr. 
The familial risk of end-stage renal disease in African 
Americans. Am J Kidney Dis 1993; 21: 387–393.
4. Price DA, Crook ED. Kidney disease in African 
Americans: genetic considerations. J Natl Med Assoc 
2002; 94: 16S–27S.
5. Brazy PC. Kidney disease and hypertension in 
blacks. Curr Opin Nephrol Hypertens 1994; 3: 
554–557.
6. Freedman BI. Familial aggregation of end-stage 
renal failure: aetiological implications. Nephrol Dial 
Transplant 1999; 14: 295–297.
7. Lei HH, Perneger TV, Klag MJ et al. Familial 
aggregation of renal disease in a population-based 
case-control study. J Am Soc Nephrol 1998; 9: 
1270–1276.
8. Spray BJ, Atassi NG, Tuttle AB, Freedman BI. Familial 
risk, age at onset, and cause of end-stage renal 
disease in white Americans. J Am Soc Nephrol 1995; 
5: 1806–1810.
9. Amos CI. Robust variance-components approach 
for assessing genetic linkage in pedigrees. Am J 
Hum Genet 1994; 54: 535–543.
10. Almasy L, Blangero J. Multipoint quantitative-trait 
linkage analysis in general pedigrees. Am J Hum 
Genet 1998; 62: 1198–1211.
11. Blangero J. Localization and identification of human 
quantitative trait loci: king harvest has surely come. 
Curr Opin Genet Dev 2004; 14: 233–240.
12. Risch N, Merikangas K. The future of genetic studies 
of complex human diseases. Science 1996; 273: 
1516–1517.
13. Klein RJ, Zeiss C, Chew EY et al. Complement 
factor H polymorphism in age-related macular 
degeneration. Science 2005; 308: 385–389.
14. Manolio TA, Brooks LD, Collins FS. A HapMap 
harvest of insights into the genetics of common 
disease. J Clin Invest 2008; 118: 1590–1605.
15. Hunt SC, Hasstedt SJ, Coon H et al. Linkage of 
creatinine clearance to chromosome 10 in Utah 
pedigrees replicates a locus for end-stage renal 
disease in humans and renal failure in the fawn-
hooded rat. Kidney Int 2002; 62: 1143–1148.
16. Hunt SC, Coon H, Hasstedt SJ et al. Linkage of 
serum creatinine and glomerular filtration rate to 
chromosome 2 in Utah pedigrees. Am J Hypertens 
2004; 17: 511–515.
17. Fox CS, Yang Q, Cupples LA et al. Genomewide 
linkage analysis to serum creatinine, GFR, and 
creatinine clearance in a community-based 
population: the Framingham Heart Study. J Am Soc 
Nephrol 2004; 15: 2457–2461.
18. Langefeld CD, Beck SR, Bowden DW et al. 
Heritability of GFR and albuminuria in Caucasians 
with type 2 diabetes mellitus. Am J Kidney Dis 2004; 
43: 796–800.
19. Placha G, Poznik GD, Dunn J et al. A genome-wide 
linkage scan for genes controlling variation in renal 
function estimated by serum cystatin C levels in 
Table 1 | Summary of selected genome-wide linkage scans for the quantitative GFR-related phenotypes
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(12 h urine collection)
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0.33–0.53 (CrCl)
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No lod scores > 3.0 for CrCl 
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MDRD-eGFR,  
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based
0.31–0.36 (eGFR),
0.46–0.72 (CrCl)
No lod scores > 3.0  
for either eGFR or CrCl 
GENOA 
(2006)27
MDRD-eGFR S-PLUS (VC) 1091 hypertensive sibships; 
50% AAs and 50% EAs
0.39–0.52 (eGFR) No lod scores > 3.0 for eGFR 
7p: lod = 3.65 (sCr in AAs only) 
Joslin 
(2006)19
Cystatin C-GFR SOLAR (VC) 63 EA diabetic families 0.36–0.45 (CC-GFR) 7p: lod = 4.0 
(diabetics and nondiabetics combined) 
2q: lod = 4.1 (diabetics only) 
10q: lod = 3.1 (diabetics only) 
AADM 
(2007)28
MDRD-eGFR,  
and CG-CrCl
SOLAR (VC) 321 diabetic sibling pairs 
from Nigeria and Ghana
0.57 (eGFR), 
0.70 (CrCl)
No lod scores > 3.0 for eGFR 
16q: lod = 3.56 (CrCl only) 
SAFDGS 
(2007)29
MDRD-eGFR,  
and CG-CrCl
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0.40 (CrCl)
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incorporation of diabetes-by-genotype 
interaction term in the model) 
FIND 
(2008)23
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Abbreviations: AA, African-American; AADM, Africa America Diabetes Mellitus Study; AI, American Indian; CC, cystatin C; CG, Cockcroft–Gault; CrCl, creatinine clearance; DHS, 
Diabetes Heart Study; EA, European-American; FIND, Family Investigation of Nephropathy and Diabetes; GENOA, Genetic Epidemiology Network of Arteriopathy; HE, Haseman–
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aAccording to Lander and Kruglyak criteria, lod ≥ 3.3 (P ≤ 4.9×10–5) is considered significant.31
1112   Kidney International (2008) 74 
commentar y
extended families with type 2 diabetes. Diabetes 
2006; 55: 3358–3365.
20. Bochud M, Elston RC, Maillard M et al. Heritability 
of renal function in hypertensive families of African 
descent in the Seychelles (Indian Ocean). Kidney Int 
2005; 67: 61–69.
21. Mottl AK, Vupputuri S, Cole SA et al. Linkage analysis 
of glomerular filtration rate in American Indians. 
Kidney Int 2008; 74: 1185–1191.  
22. Bowden DW, Colicigno CJ, Langefeld CD et al. A 
genome scan for diabetic nephropathy in African 
Americans. Kidney Int 2004; 66: 1517–1526.
23. Schelling JR, Abboud HE, Nicholas SB et al. Genome-
wide scan for estimated glomerular filtration rate 
in multi-ethnic diabetic populations: the Family 
Investigation of Nephropathy and Diabetes (FIND). 
Diabetes 2008; 57: 235–243.
24. DeWan AT, Arnett DK, Atwood LD et al. A genome 
scan for renal function among hypertensives: 
the HyperGEN study. Am J Hum Genet 2001; 68: 
136–144.
25. Leon JM, Freedman BI, Miller MB et al. Genome scan 
of glomerular filtration rate and albuminuria: the 
HyperGEN study. Nephrol Dial Transplant 2007; 22: 
763–771.
see original article on page 1128 
candesartan and renal protection: 
more than blocking angiotensin 
type 1 receptor?
Daniela Macconi1 and Giuseppe Remuzzi1,2
Chen et al. show that candesartan (Cand) displays an antioxidant 
action independent of angiotensin type 1 receptor (AT1R) blockade 
that translates into a superior renoprotection of chronic renal 
inflammation. The peculiarity of Cand in combining AT1R-blocking 
activity and an antioxidant action could have important theoretical 
implications for therapy.
Kidney International (2008) 74, 1112–1114. doi:10.1038/ki.2008.420
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Reactive oxygen species (ROS) comprise a 
series of oxygen intermediates, free radicals, 
and peroxides, produced as by-products 
of oxidative metabolism. The key initial 
step in ROS formation is the conversion 
of molecular oxygen to superoxide (O2•–), 
mainly by the electron transport chain in 
mitochondria and by nicotinamide ade-
nine dinucleotide phosphate (NAD(P)H) 
oxidase (Nox) in membrane. Originally 
discovered in phagocytes, NAD(P)H oxi-
dase is an enzymatic complex formed by 
several subunits: the membrane-associated 
proteins Nox2 and p22phox; the cytosolic 
regulatory proteins p47phox, p67phox, and 
p40phox; and the GTPase Rac1. All compo-
nents of the phagocytic NAD(P)H oxidase, 
as well as two of six proteins homologous to 
the phagocytic Nox2—Nox1 and Nox4—
are expressed in several cells of the kidney, 
including glomeruli (mesangial cells and 
podocytes) and tubules.1 ROS have been 
suggested to mediate both hemodynamic 
and nonhemodynamic actions of angi-
otensin II (Ang II), which plays a causal role 
in renal disease progression. Ang II acti-
vates renal cortical p22phox via angiotensin 
type 1 receptor (AT1R) but downregulates 
p22phox via AT2R.1 Ang II-induced ROS 
can promote endothelial dysfunction, lead-
ing to increased renal vascular resistance.1 
Importantly, ROS can function as second 
messengers for several transcription fac-
tors, including nuclear factor-κB (NF-κB), 
which activates several genes and their 
transcripts involved in renal inflamma-
tion and scarring.1 In this respect, Ang II 
acts as a stimulus of renal hypertrophy and 
extracellular matrix production.1
Chen et al.2 (this issue) have now docu-
mented that the AT1R antagonist cande-
sartan (Cand) displays anti-inflammatory 
properties through a direct antioxidant 
action independent of AT1R blockade. 
By in vitro studies using proximal tubu-
lar epithelial cells, they showed that Cand 
suppresses NF-κB-dependent chemokine 
expression induced by tumor necrosis 
factor-α, an effect that also persists after 
knockdown of AT1R (Figure 1). The mech-
anism underlying the anti-inflammatory 
effect is linked to Cand’s ability to inhibit 
ROS production and to correct the redox 
imbalance (the glutathione/glutathione 
disulfide (GSH/GSSG) ratio) induced by 
tumor necrosis factor-α or, in a similar 
manner, by hydrogen peroxide (H2O2). 
Like other ROS scavengers, N-acetyl-l-
cysteine and pyrrolidine dithiocarbamate, 
Cand exerts a direct antioxidant effect that 
is preserved in cells either transfected with 
a specific AT1R small interfering RNA or 
lacking the receptor and, importantly, is 
not shared by other angiotensin receptor 
blockers (ARBs). Additional properties 
that are unrelated to renin–angiotensin 
system (RAS) blockade have been pre-
viously discovered for another AT1R 
antagonist, telmisartan, that functions as a 
selective peroxisome proliferator-activated 
receptor-γ (PPARγ) modulator.3 Unlike 
telmisartan, Cand has a weak agonizing 
PPARγ activity.3 The finding of Chen et al.2 
that GW9662, a selective PPARγ antagonist, 
did not affect ROS inhibition induced by 
Cand rules out PPARγ as potential media-
tor of Cand’s antioxidant action. Thus, the 
antioxidant effect represents a new effect 
26. DeWan AT, Arnett DK, Miller MB et al. Refined 
mapping of suggestive linkage to renal function in 
African Americans: the HyperGEN study. Am J Hum 
Genet 2002; 71: 204–205.
27. Turner ST, Kardia SL, Mosley TH et al. Influence of 
genomic loci on measures of chronic kidney disease 
in hypertensive sibships. J Am Soc Nephrol 2006; 17: 
2048–2055.
28. Chen G, Adeyemo AA, Zhou J et al. A genome-wide 
search for linkage to renal function phenotypes in 
West Africans with type 2 diabetes. Am J Kidney Dis 
2007; 49: 394–400.
29. Puppala S, Arya R, Thameem F et al. Genotype by 
diabetes interaction effects on the detection of 
linkage of glomerular filtration rate to a region on 
chromosome 2q in Mexican Americans. Diabetes 
2007; 56: 2818–2828.
30. Freedman BI, Bowden DW, Rich SS et al. 
Genome-wide linkage scans for renal function 
and albuminuria in Type 2 diabetes mellitus: 
the Diabetes Heart Study. Diabet Med 2008; 25: 
268–276.
31. Lander E, Kruglyak L. Genetic dissection of complex 
traits: guidelines for interpreting and reporting 
linkage results. Nat Genet 1995; 11: 241–247.
